SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 - Products, Players, Markets, and Forecasts
|出版商||Greystone Research Associates||商品編碼||324586|
|SLIT片劑、自我施打及過敏免疫療法:產品、企業、市場、預測 SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 - Products, Players, Markets, and Forecasts|
|出版日期: 2015年02月17日||內容資訊: 英文||
Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitize the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. In the United States, the only licensed route of administration is subcutaneous injection (SCIT). An alternative to SCIT is sublingual immunotherapy (SLIT). The medication is kept beneath the tongue where it is absorbed into the mucosa. Though complex and not fully characterized mechanisms, administration of allergens through the oral, gingival, or sublingual mucosa can decrease the allergic response thus desensitizing the patient by modifying disease at least temporarily if not permanently (i.e. inducing tolerance). The incidence of severe or serious AE associated with SLIT is significantly lower than with SCIT such that SLIT which may be self-administered at home, while safe use of SCIT requires administration in a clinic that is capable of responding to systemic allergic reactions.